旗下有三精/哈藥/蓋中蓋/胃必治/護彤/世一堂等多個享譽市場的品牌,主營抗生素/非處方藥及保健品/傳統與現代中藥/生物醫藥/動物疫苗及醫藥商業等
哈(ha)(ha)(ha)(ha)(ha)藥(yao)(yao)集團(tuan)有(you)(you)(you)(you)(you)限公司(以下(xia)簡稱(cheng)“哈(ha)(ha)(ha)(ha)(ha)藥(yao)(yao)集團(tuan)”)為中外合(he)資企(qi)業(ye)。哈(ha)(ha)(ha)(ha)(ha)爾濱市(shi)國資委持(chi)(chi)股(gu)(gu)(gu)(gu)(gu)38.25%,中信資本(ben)冰(bing)(bing)島投(tou)(tou)(tou)資有(you)(you)(you)(you)(you)限公司持(chi)(chi)股(gu)(gu)(gu)(gu)(gu)19.1%,華平(ping)冰(bing)(bing)島投(tou)(tou)(tou)資有(you)(you)(you)(you)(you)限公司持(chi)(chi)股(gu)(gu)(gu)(gu)(gu)18.7%,哈(ha)(ha)(ha)(ha)(ha)爾濱國企(qi)重(zhong)組管(guan)理顧問有(you)(you)(you)(you)(you)限公司持(chi)(chi)股(gu)(gu)(gu)(gu)(gu)8.5%,重(zhong)慶哈(ha)(ha)(ha)(ha)(ha)珀股(gu)(gu)(gu)(gu)(gu)權投(tou)(tou)(tou)資基(ji)金合(he)伙(huo)企(qi)業(ye)(有(you)(you)(you)(you)(you)限合(he)伙(huo))持(chi)(chi)股(gu)(gu)(gu)(gu)(gu)10%,天津黑馬(ma)祺航投(tou)(tou)(tou)資管(guan)理有(you)(you)(you)(you)(you)限公司持(chi)(chi)股(gu)(gu)(gu)(gu)(gu)5%,黑龍江中信資本(ben)醫藥(yao)(yao)產業(ye)股(gu)(gu)(gu)(gu)(gu)權投(tou)(tou)(tou)資合(he)伙(huo)企(qi)業(ye)(有(you)(you)(you)(you)(you)限合(he)伙(huo))持(chi)(chi)股(gu)(gu)(gu)(gu)(gu)0.425%。旗下(xia)擁(yong)有(you)(you)(you)(you)(you)哈(ha)(ha)(ha)(ha)(ha)藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen),人民同泰兩家(jia)上市(shi)公司(截(jie)至2019年6月30日,哈(ha)(ha)(ha)(ha)(ha)藥(yao)(yao)集團(tuan)持(chi)(chi)有(you)(you)(you)(you)(you)哈(ha)(ha)(ha)(ha)(ha)藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen)46.49%股(gu)(gu)(gu)(gu)(gu)權,哈(ha)(ha)(ha)(ha)(ha)藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen)持(chi)(chi)有(you)(you)(you)(you)(you)人民同泰74.82%股(gu)(gu)(gu)(gu)(gu)權)。旗下(xia)哈(ha)(ha)(ha)(ha)(ha)藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen)于2018年9月投(tou)(tou)(tou)資3億美元(yuan)認購了美國保健品(pin)GNC發行的可轉換優(you)先股(gu)(gu)(gu)(gu)(gu),轉股(gu)(gu)(gu)(gu)(gu)完成(cheng)后,將持(chi)(chi)有(you)(you)(you)(you)(you)GNC40.1%股(gu)(gu)(gu)(gu)(gu)權,成(cheng)為其單一(yi)大股(gu)(gu)(gu)(gu)(gu)東。
集團擁(yong)有哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)總廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)三(san)精(jing)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)六廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)中藥(yao)(yao)(yao)(yao)(yao)(yao)二廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)世(shi)一(yi)堂、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)生物、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)三(san)精(jing)四(si)廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)三(san)精(jing)明(ming)水(shui)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)三(san)精(jing)千鶴、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)三(san)精(jing)兒(er)童(tong)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)疫苗等11家(jia)工(gong)業企業和哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)人民同(tong)泰、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)(yao)營銷有限(xian)公司2家(jia)商(shang)業流通企業及1家(jia)藥(yao)(yao)(yao)(yao)(yao)(yao)物研究院(yuan)。
集團主營涵蓋抗(kang)生素、非處方藥(yao)及(ji)保健(jian)品、傳(chuan)統與(yu)現代中藥(yao)、生物醫(yi)藥(yao)、動物疫苗及(ji)醫(yi)藥(yao)商(shang)業(ye)六大業(ye)務板塊。哈藥(yao)股份有1816個藥(yao)品批文和74個保健(jian)食品批文。主導產品有葡(pu)萄(tao)糖酸鈣口服(fu)(fu)溶(rong)液(ye)、葡(pu)萄(tao)糖酸鋅口服(fu)(fu)溶(rong)液(ye)、阿莫西(xi)(xi)林膠(jiao)囊、雙黃連口服(fu)(fu)液(ye)、前(qian)列地(di)爾注(zhu)射(she)液(ye)、小兒氨酚黃那敏顆粒、拉西(xi)(xi)地(di)平片(pian)、注(zhu)射(she)用鹽酸頭孢(bao)替安、布洛芬顆粒、新蓋中蓋牌(pai)高鈣片(pian)等。截至2018年(nian)底,具備(bei)年(nian)產原料藥(yao)2200噸、化藥(yao)注(zhu)射(she)劑(ji)9.8億(yi)支、中藥(yao)注(zhu)射(she)劑(ji)1.8億(yi)支、口服(fu)(fu)液(ye)20億(yi)支、片(pian)劑(ji)120億(yi)片(pian)、膠(jiao)囊131億(yi)粒、化藥(yao)顆粒劑(ji)12億(yi)袋的生產能力(li)。
所屬(shu)上(shang)市公(gong)司人(ren)(ren)民同(tong)(tong)泰主(zhu)營醫(yi)藥(yao)批(pi)發(fa)和零(ling)售(shou)業(ye)務,涵蓋(gai)(gai)中(zhong)成藥(yao)、中(zhong)藥(yao)飲片(pian)、化學藥(yao)制(zhi)(zhi)劑、抗生(sheng)素、生(sheng)物(wu)制(zhi)(zhi)品(pin)(pin)、生(sheng)化藥(yao)品(pin)(pin)、醫(yi)療(liao)器(qi)械及保健(jian)品(pin)(pin)等萬(wan)余個品(pin)(pin)規。有(you)人(ren)(ren)民同(tong)(tong)泰醫(yi)藥(yao)連鎖店(dian)314家(jia)(jia)(jia),年(nian)營業(ye)額11.5億元。其下屬(shu)藥(yao)品(pin)(pin)批(pi)發(fa)企(qi)業(ye)與黑(hei)龍(long)江(jiang)省(sheng)內(nei)1000多(duo)家(jia)(jia)(jia)醫(yi)療(liao)機構(gou),1900多(duo)家(jia)(jia)(jia)第(di)三終端(duan),近700家(jia)(jia)(jia)商業(ye)客戶開展緊密合作,三級以上(shang)醫(yi)院的(de)市場覆(fu)蓋(gai)(gai)率95%以上(shang),二級以上(shang)醫(yi)院的(de)市場覆(fu)蓋(gai)(gai)率達90%以上(shang)。其物(wu)流配(pei)送中(zhong)心(xin)是黑(hei)龍(long)江(jiang)省(sheng)、東北地區(qu)較大的(de)現代化醫(yi)藥(yao)物(wu)流中(zhong)心(xin),儲存能(neng)力40萬(wan)箱,年(nian)吞吐能(neng)力300億元。根(gen)據(ju)商務部發(fa)布(bu)的(de)《2018年(nian)藥(yao)品(pin)(pin)流通行(xing)(xing)(xing)業(ye)運行(xing)(xing)(xing)統計(ji)分析報告》顯(xian)示(shi),2018年(nian)人(ren)(ren)民同(tong)(tong)泰批(pi)發(fa)業(ye)務收入在全國藥(yao)品(pin)(pin)批(pi)發(fa)企(qi)業(ye)中(zhong)排(pai)行(xing)(xing)(xing)第(di)27位,零(ling)售(shou)業(ye)務銷售(shou)總額在全國零(ling)售(shou)企(qi)業(ye)中(zhong)排(pai)行(xing)(xing)(xing)第(di)23位。
集團還擁(yong)有(you)占地(di)面(mian)積4萬平(ping)方(fang)米(mi),建(jian)筑面(mian)積3.8萬平(ping)方(fang)米(mi)的新藥研發基地(di)——哈藥集團技術中心,下(xia)設生物(wu)藥、化學原(yuan)料藥、化學制劑、保健食品(pin)、質量檢測(ce)分(fen)析5個研發平(ping)臺,擁(yong)有(you)發明授權專利25件,近5年獲得生產批(pi)件6個,臨床批(pi)件17個。
截至2018年(nian)末(mo),哈藥(yao)集(ji)團在職員(yuan)(yuan)(yuan)工(gong)(gong)總(zong)數18618人(ren)。其中,正式員(yuan)(yuan)(yuan)工(gong)(gong)15968人(ren),臨時用工(gong)(gong)人(ren)員(yuan)(yuan)(yuan)2650人(ren)。擁有中級以上(shang)職稱的3245人(ren),占(zhan)(zhan)正式員(yuan)(yuan)(yuan)工(gong)(gong)的20%;大(da)學本科以上(shang)學歷的4916人(ren),占(zhan)(zhan)正式員(yuan)(yuan)(yuan)工(gong)(gong)的31%,其中博士研究生11人(ren),碩士研究生398人(ren)。
2018年,哈藥集(ji)團資(zi)產(chan)總額(e)143.65億(yi)元(yuan)(yuan);固定資(zi)產(chan)35.63億(yi)元(yuan)(yuan);凈資(zi)產(chan)83.03億(yi)元(yuan)(yuan);實現(xian)營業收入111.63億(yi)元(yuan)(yuan);利潤總額(e)6.36億(yi)元(yuan)(yuan);凈利潤4.40億(yi)元(yuan)(yuan),利稅13.11億(yi)元(yuan)(yuan)。